Abstract 2799: Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation

Abstract The majority (up to 85%) of colorectal cancer (CRC) patients have a microsatellite stable (MSS) tumor phenotype, which is a poor responder to immune checkpoint blockade (ICB). Therefore, there is a need to identify novel checkpoints in the tumor microenvironment, such as ST2 (Stimulation 2, IL33 receptor). We demonstrated ST2 to be prominently expressed on human tumor cells, especially MSS tumors, through multiplex immunofluorescence staining of CRC patient samples and publicly available datasets. Using CRC patient-derived organoids, we established that activation of tumoral IL33/ST2 signaling conferred tumor cell protection from T cell-mediated killing. To investigate the mechanistic basis of how tumor cells escape T cell killing, we used colonoscopy-induced, orthotopic murine tumors. We uncovered that IL33/ST2 signaling reduced antigen presentation, driven by reduced immunoproteasome activity. Removing tumoral ST2 signaling using CRISPR/Cas9-gene editing leads to significant tumor growth control and increased infiltration of T cells with a reduced terminally exhausted phenotype. Altogether, these findings indicate ST2 as a potential, novel checkpoint target on tumor cells to enlarge the pool of patients benefiting from ICB. Citation Format: Alyssa Mauri Cornista, Tao Yu, Zhuolong Zhou, Nikša Roki, Alberto Sigler, David M. Suissa, Haniyeh Eyvani, George E. Sandusky, Rimpi Khurana, Yan Guo, Molly Dalzell, Shyamananda Singh Mayengbam, Prasenjit Dey, Christine Rafie, Erietta Stelekati, Jashodeep Datta, Saratchandra S. Khumukcham, Jatin Roper, Nivedh Paluvoi, Sandro Satta, Daniel Bilbao Cortes, Alejandro Villarino, Kevin Van der Jeught. Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2799.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-2799
Primary Topic
IL-33, ST2, and ILC Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 2799: Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation

Zhuolong Zhou, Kevin Van der Jeught, Nivedh Paluvoi, Haniyeh Eyvani et al.
Cancer Research
IL-33, ST2, and ILC Pathways
article

Abstract 2799: Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation

Zhuolong Zhou, Kevin Van der Jeught, Nivedh Paluvoi, Haniyeh Eyvani, Sandro Satta, Molly Dalzell, Shyamananda Singh Mayengbam, Alejandro V. Villarino, Alberto Sigler, Daniel Bilbao Cortes, Rimpi Khurana, Erietta Stelekati, Prasenjit Dey, Saratchandra Singh Khumukcham, Christine I. Rafie, Nikša Roki, Jatin Roper, Alyssa Mauri Cornista, David M. Suissa, G. Sandusky, Tao Yu, Yan Guo, Jashodeep Datta
article en

Abstract

Abstract The majority (up to 85%) of colorectal cancer (CRC) patients have a microsatellite stable (MSS) tumor phenotype, which is a poor responder to immune checkpoint blockade (ICB). Therefore, there is a need to identify novel checkpoints in the tumor microenvironment, such as ST2 (Stimulation 2, IL33 receptor). We demonstrated ST2 to be prominently expressed on human tumor cells, especially MSS tumors, through multiplex immunofluorescence staining of CRC patient samples and publicly available datasets. Using CRC patient-derived organoids, we established that activation of tumoral IL33/ST2 signaling conferred tumor cell protection from T cell-mediated killing. To investigate the mechanistic basis of how tumor cells escape T cell killing, we used colonoscopy-induced, orthotopic murine tumors. We uncovered that IL33/ST2 signaling reduced antigen presentation, driven by reduced immunoproteasome activity. Removing tumoral ST2 signaling using CRISPR/Cas9-gene editing leads to significant tumor growth control and increased infiltration of T cells with a reduced terminally exhausted phenotype. Altogether, these findings indicate ST2 as a potential, novel checkpoint target on tumor cells to enlarge the pool of patients benefiting from ICB. Citation Format: Alyssa Mauri Cornista, Tao Yu, Zhuolong Zhou, Nikša Roki, Alberto Sigler, David M. Suissa, Haniyeh Eyvani, George E. Sandusky, Rimpi Khurana, Yan Guo, Molly Dalzell, Shyamananda Singh Mayengbam, Prasenjit Dey, Christine Rafie, Erietta Stelekati, Jashodeep Datta, Saratchandra S. Khumukcham, Jatin Roper, Nivedh Paluvoi, Sandro Satta, Daniel Bilbao Cortes, Alejandro Villarino, Kevin Van der Jeught. Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2799.

Cancer ResearchVol. 86(7_Supplement)
Roswell Park Comprehensive Cancer Center (US), University of Indianapolis (US), University of Miami (US), Duke Medical Center (US), Sylvester Comprehensive Cancer Center (US), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US)
No poverty
Openalex Percentile: Top 31%
IL-33, ST2, and ILC Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.